SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Check Before You Invest : Krebs Biochemicals & Industries Ltd

BSE: 524518 NSE: KREBSBIO ISIN: INE268B01013
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Krebs Biochemicals & Industries Ltd belong to?
Krebs Biochemicals & Industries Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Krebs Biochemicals & Industries Ltd a good quality company?
Krebs Biochemicals & Industries Ltd is a weak quality company, based on a inconsistent 10 year financial track record.
Q.3 Is Krebs Biochemicals & Industries Ltd undervalued or overvalued?
Krebs Biochemicals & Industries Ltd appears Undervalued, as its key valuation ratios are below with their past averages.
Q.4 Is Krebs Biochemicals & Industries Ltd a good buy now?
Krebs Biochemicals & Industries Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd revenue growth is -14.1% for FY-2025 , which is below its 5 year CAGR of 5.3% , indicating slower growth.
Q.2 Gross Profit margin of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd Gross profit margin which is the profit after deduction of direct costs, is -46.7% for FY-2025 , which is below its 5 year median of -43.3% , indicating decreasing margins.
Q.3 Operating Profit Margin of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is -34.7% for FY-2025 , which is below its 5 year median of -32.73% indicating decreasing margins.
Q.4 Net Profit Margin of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd Net Profit Margin is -62.2% for FY-2025 , is below with its 5 year median of -52.81%, indicating decreasing margins.
Current Level Historic Median
Gross Profit Margin -46.7 -43.3
Operating Profit Margin -34.7 -32.73
Net Profit Margin -62.2 -52.81
Q.5 Return on Asset of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd Return on Asset is -15.52%, which is in line with its 5 year historical median of -15.52%, indicating stable asset utilization efficiency.
Q.6 Return on Equity (ROE) of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd Return on equity is 0% for FY-2025 , which is in line with its historical median of 0%, indicating the business is making similar use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd Return on capital employed is -29.92% for FY-2025 , which is below its estimated weighted average cost of capital(WACC) 14%, indicating value preservation.
Q.8 Cash conversion cycle of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd Cash conversion cycle is -36 days, below its historical median of 0 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.25 0.29
ROE - -
ROCE -29.92 -29.92
Cash Conversion Cycle -36 days -
Q.9 Debt to Equity ratio of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd Debt-to-Equity ratio is -1.45 , which is lower with the industry average of 0.15 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd Debt to cash flow from operations is -26.89 , which is at a unhealthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Krebs Biochemicals & Industries Ltd?
Promoters hold 72.74% of the Krebs Biochemicals & Industries Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Krebs Biochemicals & Industries Ltd vs industry peers?
Krebs Biochemicals & Industries Ltd revenue CAGR is 5.33% , compared to the industry median CAGR of 5.51% , indicating slower growth and losing its market share.
Profit Metrics
Current Level Industry Median
Revenue 43.3 138.8
Gross Profit -20.1 16.2
Operating Profit -15 16
Net Profit -27 5.3
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.25 0.79
ROE - 9.17
ROCE -29.92 11.78
Cash Conversion Cycle (days) -36.42 76

Valuation & price assessment

Q.1 Stock return of Krebs Biochemicals & Industries Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of -4.6% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price -4.6% -12.2% -6.3% -25.4%
Q.3 Valuation ratios of Krebs Biochemicals & Industries Ltd vs historical?
The current P/E is similar that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings - - 40.28
Price to Book -0.84 -1.44 2.77
Price to Sales 5.84 4.04 2.65
EV to EBITDA -36.95 -24.88 15.67

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×